Baird Raises Price Target for Medtronic to $109
TL;DR
Baird analyst David Rescott raised Medtronic's price target to $109 from $103, keeping a Neutral rating. This reflects ongoing analyst confidence in the medical device company's steady market performance.
Tags
Baird analyst David Rescott raised Medtronic's (MDT) price target to $109 from $103, maintaining a Neutral rating. The historical ratings have shown consistent increases in price targets from various analysts, reflecting steady confidence in the company's market performance. Medtronic develops and manufactures therapeutic medical devices for chronic diseases, with a portfolio including pacemakers, defibrillators, stents, insulin pumps, spinal fixation devices, and more. The average target price for Medtronic PLC is $105.20, with a high estimate of $120.00 and a low estimate of $81.00.
